Elitica Escitalopram Oxalate Oral Solution

1. Indications and Usage
Major Depressive Disorder: Indicated for the treatment of major depressive disorder.
Generalized Anxiety Disorder: Indicated for the treatment of generalized anxiety disorder.
2. Dosage and Administration
Adults: The recommended starting dose is 10 mg once daily. The dose can be increased to a maximum of 20 mg once daily based on individual response. It can be taken with or without food.
Elderly (≥65 years): The recommended dose is 5 mg once daily, with a maximum of 10 mg once daily.
Hepatic Impairment: For mild to moderate hepatic impairment, the starting dose is 5 mg once daily. For severe hepatic impairment, caution is advised when increasing the dose.
Renal Impairment: No dose adjustment is required for mild to moderate renal impairment. Severe renal impairment requires cautious use.
Administration: The oral solution should be measured using the provided measuring device.
3. Mechanism of Action
Escitalopram is the S-enantiomer of the racemic citalopram. It acts as a highly selective serotonin reuptake inhibitor (SSRI). By blocking the reuptake of serotonin (5-HT) into presynaptic neurons, it increases the concentration of serotonin in the synaptic cleft, thereby enhancing serotonergic neurotransmission and alleviating depressive and anxiety symptoms.
4. Safety and Warnings
Suicidality: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults. Close monitoring for clinical worsening and suicidality is necessary, especially during the initial months of treatment.
Serotonin Syndrome: Concomitant use with other serotonergic drugs can lead to serotonin syndrome, a potentially life-threatening condition characterized by mental status changes, autonomic instability, and neuromuscular abnormalities.
QT Prolongation: Escitalopram can prolong the QT interval, increasing the risk of ventricular arrhythmias (e.g., Torsades de Pointes), particularly at higher doses.
Discontinuation Syndrome: Abrupt discontinuation may lead to withdrawal symptoms (e.g., dizziness, nausea, headache). Tapering is recommended when stopping the drug.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include nausea, insomnia, somnolence, erectile dysfunction, ejaculation disorder, dry mouth, constipation, diarrhea, fatigue, and increased sweating.
Clinical Research: Clinical trials have demonstrated that escitalopram is effective in reducing symptoms of depression and anxiety, with a favorable tolerability profile compared to other SSRIs.
6. Drug Interactions
MAOIs: Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome. A washout period is required.
QT-Prolonging Drugs: Caution is advised when used with other drugs known to prolong the QT interval (e.g., class IA and III antiarrhythmics, antipsychotics).
CYP2C19 Inhibitors: Drugs that inhibit CYP2C19 (e.g., omeprazole, cimetidine) may increase escitalopram plasma concentrations.
7. Pharmaceutical Information
Composition: The active ingredient is escitalopram oxalate. The solution contains excipients such as propylene glycol, sorbitol, and purified water.
Appearance: It is a clear, colorless to slightly yellowish liquid.
Storage: Store below 25°C and protect from light.